| Christopher Gilmartin, O.d., Inc | |
|
822 Cass St, Suite B, Traverse City, MI 49684-3230 | |
| (231) 946-6095 | |
| Not Available |
| Full Name | Christopher Gilmartin, O.d., Inc |
|---|---|
| Type | Facility |
| Speciality | Optometrist - Corneal And Contact Management |
| Location | 822 Cass St, Traverse City, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023486545 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WC0802X | Optometrist - Corneal And Contact Management | 4901004823 (Michigan) | Primary |
| Provider Name | Christopher Andrew Gilmartin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1528396900 PECOS PAC ID: 5890824924 Enrollment ID: I20160329002710 |
News Archive
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Two multinational clinical studies indicate that the RDI's system for predicting how HIV and AIDS patients will respond to different drugs could be a useful tool with potential clinical and economic benefits. The studies, published in the January issue of AIDS Patient Care and STDs, involved highly experienced physicians in the USA, Canada and Italy who used the system to help them select the optimum combination of HIV drugs for patients whose therapy was failing.
University of Minnesota researchers have discovered how a gene that suppresses the development of melanoma and other human cancers works. The study points the way to treatments based on the function of the gene.
Reduced levels of a chaperone protein might have implications for the development and progression of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia, according to new research from investigators at the University of Alabama at Birmingham.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Gilmartin, O.d., Inc 822 Cass St, Suite B, Traverse City, MI 49684-3230 Ph: (231) 946-6095 | Christopher Gilmartin, O.d., Inc 822 Cass St, Suite B, Traverse City, MI 49684-3230 Ph: (231) 946-6095 |
News Archive
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Two multinational clinical studies indicate that the RDI's system for predicting how HIV and AIDS patients will respond to different drugs could be a useful tool with potential clinical and economic benefits. The studies, published in the January issue of AIDS Patient Care and STDs, involved highly experienced physicians in the USA, Canada and Italy who used the system to help them select the optimum combination of HIV drugs for patients whose therapy was failing.
University of Minnesota researchers have discovered how a gene that suppresses the development of melanoma and other human cancers works. The study points the way to treatments based on the function of the gene.
Reduced levels of a chaperone protein might have implications for the development and progression of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia, according to new research from investigators at the University of Alabama at Birmingham.
› Verified 1 days ago
Jennifer Ann Lintz, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 929 Business Park Dr, Traverse City, MI 49686 Phone: 231-947-6246 Fax: 231-947-8864 | |
Julie Slough Runstrom, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3200 S Airport Rd W, #146, Traverse City, MI 49684 Phone: 231-941-7788 Fax: 231-941-0893 | |
Dr. Christopher Michael Reed, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 527 W Front St, Traverse City, MI 49684 Phone: 231-947-8667 | |
Carl J Erickson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5199 N Royal Dr, Traverse City, MI 49684 Phone: 231-935-8101 Fax: 231-935-0955 | |
Full Spectrum Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 328 Munson Ave, Traverse City, MI 49686 Phone: 231-946-8460 Fax: 231-946-8507 | |
Marc L Austhof Od Eye Care Services Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 2640 Crossing Cir, Traverse City, MI 49684 Phone: 231-933-7195 Fax: 231-933-7197 |